Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.

Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C.

Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017.

2.

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.

Tan RH, Kril JJ, Yang Y, Tom N, Hodges JR, Villemagne VL, Rowe CC, Leyton CE, Kwok JBJ, Ittner LM, Halliday GM.

Alzheimers Dement (Amst). 2017 May 29;9:10-20. doi: 10.1016/j.dadm.2017.05.005. eCollection 2017.

3.

18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, Sami S, Cope TE, Bevan-Jones WR, Jones PS, Arnold R, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Brain. 2017 Mar 1;140(3):781-791. doi: 10.1093/brain/aww340.

4.

Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.

Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD.

Mov Disord Clin Pract. 2016 Jul-Aug;3(4):367-375. Epub 2016 Jan 5.

5.

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.

Witte MM, Foster NL, Fleisher AS, Williams MM, Quaid K, Wasserman M, Hunt G, Roberts JS, Rabinovici GD, Levenson JL, Hake AM, Hunter CA, Van Campen LE, Pontecorvo MJ, Hochstetler HM, Tabas LB, Trzepacz PT.

Alzheimers Dement (Amst). 2015 Jul 26;1(3):358-67. doi: 10.1016/j.dadm.2015.06.006. eCollection 2015 Sep.

6.

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.

Adamczuk K, Schaeverbeke J, Vanderstichele HM, Lilja J, Nelissen N, Van Laere K, Dupont P, Hilven K, Poesen K, Vandenberghe R.

Alzheimers Res Ther. 2015 Dec 18;7(1):75. doi: 10.1186/s13195-015-0159-5.

7.

Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.

Schöll M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, Wall A, Graff C, Långström B, Nordberg A.

Sci Rep. 2015 Nov 10;5:16404. doi: 10.1038/srep16404.

8.

18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF, Dorbala S.

Circ Cardiovasc Imaging. 2015 Aug;8(8). pii: e002954. doi: 10.1161/CIRCIMAGING.114.002954.

9.

Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.

Albin RL, Fisher-Hubbard A, Shanmugasundaram K, Koeppe RA, Burke JF, Camelo-Piragua S, Lieberman AP, Giordani B, Frey KA.

Ann Neurol. 2015 Nov;78(5):824-30. doi: 10.1002/ana.24481. Epub 2015 Aug 25.

10.

Amyloid in dementia associated with familial FTLD: not an innocent bystander.

Naasan G, Rabinovici GD, Ghosh P, Elofson JD, Miller BL, Coppola G, Karydas A, Fong J, Perry D, Lee SE, Yokoyama JS, Seeley WW, Kramer JH, Weiner MW, Schuff N, Jagust WJ, Grinberg LT, Pribadi M, Yang Z, Sears R, Klein E, Wojta K, Rosen HJ.

Neurocase. 2016;22(1):76-83. doi: 10.1080/13554794.2015.1046458. Epub 2015 Jun 4.

11.

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ.

JAMA. 2015 May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669.

12.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

13.

In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging.

Barrio JR, Small GW, Wong KP, Huang SC, Liu J, Merrill DA, Giza CC, Fitzsimmons RP, Omalu B, Bailes J, Kepe V.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E2039-47. doi: 10.1073/pnas.1409952112. Epub 2015 Apr 6. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2981.

14.

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.

Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR Jr, Dickson DW.

Brain. 2015 May;138(Pt 5):1370-81. doi: 10.1093/brain/awv050. Epub 2015 Mar 23.

15.

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy.

Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, Santos M, Miller ZA, Bettcher BM, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.

Ann Neurol. 2015 Feb;77(2):338-42. doi: 10.1002/ana.24321. Epub 2014 Dec 17.

16.

Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.

Beach TG, Schneider JA, Sue LI, Serrano G, Dugger BN, Monsell SE, Kukull W.

J Neuropathol Exp Neurol. 2014 Oct;73(10):948-53. doi: 10.1097/NEN.0000000000000114.

17.

Dementia with Lewy bodies: basis of cingulate island sign.

Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, Lesnick TG, Senjem ML, Gunter JL, Smith GE, Knopman DS, Jack CR Jr, Dickson DW, Petersen RC, Kantarci K.

Neurology. 2014 Aug 26;83(9):801-9. doi: 10.1212/WNL.0000000000000734. Epub 2014 Jul 23.

18.

Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects.

Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53. doi: 10.1016/j.jalz.2013.09.011. Epub 2014 Jan 10.

19.

Associations between serum cholesterol levels and cerebral amyloidosis.

Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W.

JAMA Neurol. 2014 Feb;71(2):195-200. doi: 10.1001/jamaneurol.2013.5390.

20.

Practical utility of amyloid and FDG-PET in an academic dementia center.

Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, O'Neil JP, Janabi M, Huang EJ, Trojanowski JQ, Vinters HV, Gorno-Tempini M, Seeley WW, Boxer AL, Rosen HJ, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD.

Neurology. 2014 Jan 21;82(3):230-8. doi: 10.1212/WNL.0000000000000032. Epub 2013 Dec 18.

Supplemental Content

Loading ...
Support Center